Moderna Stock Jumps After FDA Reverses Course on Flu Shot

Key Takeaways Moderna shares climbed 6% after the FDA agreed to review its mRNA-1010 flu vaccine filing.FDA reversed last week's refusal; decision on mRNA-1010 is due by Aug. 5, 2026.mRNA-1010 seeks full nod for 50-64 and accelerated approval for 65, launch eyed for 2026/2027.Shares of Moderna (MRNA) rose 6% on Wednesday after the company announced that the FDA agreed to review its regulatory filing seeking approval for its seasonal influenza vaccine, mRNA-1010. A final decision is expected by Aug. 5, 2026. ...